%20(1)%20(1).svg)
How ASMD Can Impact Quality of Life and Average Life Expectancy
Learn more
ASMD: Your differential could make all the difference
A progressive genetic disease with multisystemic complications and varying severity
ASMD (acid sphingomyelinase deficiency) can result in severe multisystemic complications, including morbidity and early mortality.1,2
Early diagnosis of ASMD is imperative
Symptoms of ASMD are variable and often overlap with other conditions, leading to frequent diagnostic delays and missed diagnoses.1-3
Include ASMD and Gaucher disease in your differential diagnosis and parallel test
With patients experiencing average diagnostic delays of ~5 years, parallel testing can help facilitate timely diagnosis and symptom management.2,3,a
aBased on a prospective, cross-sectional survey of 59 ASMD type B patients.
Overview
Understanding ASMD: A progressive, potentially life-threatening genetic disease
Multiorgan impact and diagnostic delays can have severe health consequences2
ASMD (acid sphingomyelinase deficiency), historically known as Niemann-Pick disease Types A, A/B, and B, is a genetic disease with progressive and multisystemic symptoms that can lead to early mortality. The disease is caused by deficiency of the enzyme acid sphingomyelinase (ASM), resulting in buildup of the substrate sphingomyelin in cells. Accumulation of sphingomyelin impacts major organs, which may include the liver, lungs, spleen, blood and gastrointestinal system.1
Missed diagnoses and diagnostic delays are common for patients with ASMD, who face an average delay of ~5 years.2,3,a
aBased on a prospective, cross-sectional survey of 59 ASMD type B patients
Types of ASMD
ASMD is a spectrum of disease, with 3 types that vary in age of onset, rate of progression, and impact on lifespan.1,2,4
| TYPE A | TYPE A/B | TYPE B (most commonb) | |
| Onset | Early infancy | Infancy to childhood | Infancy to adulthood |
| Phenotype | Rapidly progressive, severe multiorgan involvement and neurodegeneration | Variably progressive, variable multiorgan disease and neurodegeneration | Slower progressive, variable multiorgan disease with little to no neurological involvement |
| Life expectancy | 2 to 3 years of age | Childhood to mid-adulthood | Childhood to late adulthood |
bBased on patient population from a multicenter, historical cohort study (N=100).
Regardless of ASMD type, deficient ASM activity can lead to lifelong, multisystemic complications.2
Pathogenesis of ASMD
ASM enzyme deficiency is the underlying cause of ASMD
ASMD is caused by pathogenic variants in the SMPD1 gene – which encodes acid sphingomyelinase (ASM) – resulting in ASM enzyme deficiency.2
.jpg)
ASM breaks down sphingomyelin in the lysosomes of the cell.2
Sphingomyelin plays an important role in cellular processes, such as cell cycle regulation, cell signaling, and apoptosis.5,6
Decreased ASM activity leads to buildup of sphingomyelin.1
Lysosomal accumulation of sphingomyelin in the monocyte-macrophage system causes damage that can result in life-threatening, multiorgan complications.1
The following video depicts the mechanism of ASMD pathogenesis
ASMD symptoms can be multisystemic and life‑threatening
Suspect ASMD if a patient presents with a combination of these signs and symptoms.1,4
Frequency of ASMD patients experiencing hallmark signs and symptoms1,2,a
aSymptom prevalence data for splenomegaly, interstitial lung disease, hepatomegaly, thrombocytopenia, and pediatric growth delay are only for patients with ASMD type B. Gastrointestinal issues symptom prevalence is for all ASMD types.1,4
The multisystemic symptoms of ASMD can result in severe damage over time. Early detection is the first step to prompt diagnosis and symptom management.1,2
ASMD signs and symptoms commonly mimic other conditions2
Symptoms of ASMD often overlap those of other lysosomal storage diseases, hematologic malignancies, and diseases of the heart and lungs. As a result, missed diagnoses and diagnostic delays are common.2
Conditions that share the hallmark signs and symptoms of ASMD type B include Gaucher disease type 1, acute lymphoblastic leukemia, non-Hodgkin lymphoma, chronic hepatitis B, cystic fibrosis, and congestive heart failure.2
Gaucher disease – another rare lysosomal storage disease – shares significant phenotypic overlap with ASMD. Similar to ASMD, Gaucher disease is characterized by multisystemic and progressive symptoms that vary in onset and clinical presentation.2,9
ASMD and Gaucher disease often present with symptoms similar to more commonly seen conditions1,2,9-23
The dots in the table above represent the most commonly presenting symptoms in each of the respective diseases (ASMD type B and Gaucher disease type 1).2,3,9-11,14
bThis symptom is not seen as commonly in Gaucher disease type 1.
Include ASMD and Gaucher disease in your differential diagnosis, along with other, more commonly seen and considered conditions. Your differential diagnosis can help patients find the answer to their progressive symptoms.
Due to the phenotypic overlap between ASMD and Gaucher disease, guidelines recommend parallel testing.2
Suspect ASMD? Test to know
Early diagnosis is key to enabling appropriate disease monitoring and symptom management1,2
Include ASMD and Gaucher disease in your differential diagnosis and parallel test
ASMD symptoms vary in onset and clinical presentation, and often overlap with those of more commonly seen and considered conditions. Due to this variability and symptom overlap, diagnostic delays are common.1,2,10
Diseases of the heart, liver, lungs, and hematologic malignancies may exhibit symptoms similar to ASMD. Another lysosomal storage disease, Gaucher disease, shares significant symptom overlap with ASMD.2
Guidelines recommend parallel testing for ASMD and Gaucher disease.
With patients experiencing average diagnostic delays of ~5 years, parallel
testing can help facilitate timely diagnosis and symptom management.2,10,a
aBased on a prospective, cross-sectional survey of 59 ASMD type B patients.
A diagnostic approach for ASMD based on expert guidelines2:
Splenomegaly and hepatomegaly are often the first presenting signs of ASMD and Gaucher disease. Further evaluations may reveal other compounding symptoms that should prompt diagnostic testing.2
HDL-C=high-density lipoprotein cholesterol.
Adapted from McGovern MM et al. Genet Med. 2017;19(9):967-974.
Testing can be the first step to appropriate symptom management
ASMD diagnostic testing is a straightforward process, and may get patients the answers they need to begin managing their symptoms appropriately. Over time, ASMD symptoms can progress and lead to increased disease burden and risk of death.1,2
Expert guidelines recommend parallel testing for both ASMD and Gaucher disease due to symptom overlap.2
Diagnostic testing for ASMD is simple2
|
Adapted from McGovern MM et al. Genet Med. 2017;19(9):967-974.
aLimitations to DBS testing include the potential effects of anemia and recent transfusions on results. Skin fibroblasts can be used in equivocal cases.
Guidelines recommend parallel testing for both ASMD and Gaucher disease2,10,b
bGuidelines are based on a consensus of opinion from an international group of experts in ASMD.
cGenetic testing can also be performed as additional diagnostic confirmation for ASMD. However, gene sequencing should not be a substitute for the biochemical enzyme assay.
Labs across the United States offer diagnostic tests for ASMD and Gaucher disease.
Support for Healthcare Providers
Have a question or want additional information? A Sanofi representative is available to answer your disease- or product-related questions. Click the link below to complete a request.
Downloadable Resources
|
Symptoms & Diagnosis |
Monitoring |
For Hepatologists |
For Pulmonologists |
Medical Information
Sanofi's Medical Information Department can provide information on diagnostic testing, pharmacovigilance/safety, and ASMD.
|
Visit our Medical Information Website Please call 8 AM until 6 PM EST, Monday through Friday: 1-800-745-4447, option 2 (toll-free)/1-617-768-9000, option 2 |
Support for Your Patients
CareConnectTM Personalized Support Services – Connected Care Personalized To Your Patients
CareConnect is a free, voluntary and confidential support program for eligible patients and families living with certain lysosomal storage disorders (LSDs).
Connected Education: Comprehensive disease education from diagnosis and beyond for individuals, families, and communities.
Connected Team: Experts who connect the dots between specialists, insurance, and appointments for a less fragmented care experience.
Connected Experience: Programs designed to support patients by connecting them with experts and the community to navigate life transitions and manage treatment.
If affording treatment is an issue, CareConnect may be able to help eligible patients access financial assistance. To learn more about our range of support offerings, connect with us at careconnectpss.com/hcp, call 1-800-745-4447, option 3, or email info@careconnectpss.com
Patient website
Sanofi is committed to providing you with materials to help educate your patients about lysosomal storage disorders. A variety of patient educational materials are available to help patients understand ASMD, its symptoms, and management.
References: 1. McGovern MM et al. Orphanet J Rare Dis. 2017;12(1):41. 2. McGovern MM, et al. Genet Med. 2017;19(9):967-974. 3. McGovern MM et al. Pediatrics. 2008;122(2):e341-e349. 4. Cox GF et al. JIMD Rep. 2018;41:119-129. 5. Eyester KM. Adv Physiol Educ. 2007;31(1):5-16. 6. Schuchman EH et al. Mol Genet Metab. 2017;120(1-2):27-33. 7. McGovern MM et al. Neurology. 2006;66(2):228-232. 8. Cassiman D et al. Mol Genet Metab. 2016;118(3):200-213. 9. Kaplan P et al. Eur J Pediatr. 2013;172:447-458. 10. Mistry PK et al. Am J Hematol. 2011;86(1):110-115. 11. Grabowski GA et al. http://ommbid.mhmedical.com/content.aspx?bookid=474§ionid=45374148. Accessed March 2022. 12. Stirnemann J et al. Int J Mol Sci. 2017;18(2):441. 13. De Fost M et al. Atherosclerosis. 2009;204(1):267-272. 14. McGovern MM et al. Orphanet J Rare Dis. 2021;16(212):1-14. 15. Leukemia & Lymphoma Society. https://www.lls.org/leukemia/acute-lymphoblastic-leukemia/signs-and-symptoms. July 23, 2025. 16. Larson RA, Anastasi J. Acute lymphoblastic leukemia: clinical presentation, diagnosis, and classification. In: Estey EH, Faderl SH, Kantarjian HM, eds. Hematologic Malignancies: Acute Leukemias. Springer-Verlag; 2008:109-118. Hematologic Malignancies: Acute Leukemias. 2008. 17. Leukemia & Lymphoma Society. https://www.lls.org/lymphoma/non-hodgkin-lymphoma/signs-and-symptoms. Accessed March 2022. 18. American Cancer Society. https://www.cancer.org/cancer/non-hodgkin-lymphoma/treating/palliative-care.html. Accessed March 2022. 19. Shankland KR et al. Lancet. 2012;380(9844):848-857. 20. National Cancer Institute, National Institutes of Health. https://www.cancer.gov/types/lymphoma/patient/adultnhl-treatment-pdq. Accessed March 2022. 21. Liang TJ. Hepatology. 2009;49(5 suppl):S13-S21. 22. Watson RDS et al. BMJ. 2000;320(7229):236-239. 23. Kobelska-Dubiel N et al. Prz Gastroenterol. 2014;9(3):136-141.
MAT-US-2011636-v3.0-08/2025
